By leveraging the high specificity of the FMC63 scFv and the broad, multivalent recognition capacity of NKG2D, the tandem CAR is uniquely positioned to enhance targeting across diverse tumor contexts, particularly those exhibiting heterogeneous or downregulated antigen expression. This evidence concerns the gene KLRK1 and neoplasm.